The deal, valued at up to $1.05 billion, comprises an $800 million upfront payment and an additional $250 million contingent upon r...
Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited (BSE code: 532523, NSE: BIOCON),...
Curio Bioscience announced the commercialization of the world’s first technology that spatially contextualizes single-cell sequencing data, lev...
The new registry will prospectively collect detailed patient-level data enabling assessment of the natural history of the disease and treatment patterns, a...
Rob Truckenmiller, Senior Vice President, Head of US Vaccines, GSK, emphasized the importance of collaborative efforts and fi...
After an initial expansion of the CordenPharma Frankfurt site for non-GMP manufacturing in 2020, and because of sustained success and exemplary perfor...
New site in Cajamar, São Paulo has 2.5 times more storage capacity than previous space in Cotia, São Paulo 13,000 square-meters space for ...
“GenAI is poised to revolutionize how insights leaders harness the collective power of all their research investments to make quick, informed decisio...
Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, an...
Targeted base editing of mammalian mtDNA is a powerful technology f...
Polpharma Biologics' investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio® ...
In a bold move, Vaccinex has forged eight new antibody discovery agreements with leading pharmaceutical and biotechnology companies, as well as str...
"This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pa...
Exscientia plc (Nasdaq: EXAI), a frontrunner in AI-driven precision medicine, has officially announced a significant leadership adjustment and the submissi...
© 2025 Biopharma Boardroom. All Rights Reserved.
